A number of other brokerages also recently issued reports on ENDP. BidaskClub raised Endo International from a “strong sell” rating to a “sell” rating in a report on Friday, October 18th. Morgan Stanley set a $2.00 price target on Endo International and gave the company a “sell” rating in a report on Friday, August 9th. Royal Bank of Canada reissued a “hold” rating and issued a $6.00 price target on shares of Endo International in a report on Thursday, August 8th. Finally, Mizuho restated a “hold” rating and issued a $6.00 price objective on shares of Endo International in a research report on Wednesday, August 7th. Four equities research analysts have rated the stock with a sell rating, eleven have issued a hold rating and two have assigned a buy rating to the company’s stock. The stock currently has an average rating of “Hold” and a consensus price target of $7.89.
Shares of NASDAQ:ENDP opened at $4.19 on Thursday. Endo International has a 12-month low of $1.97 and a 12-month high of $16.98. The company has a market capitalization of $1.10 billion, a PE ratio of 1.45 and a beta of 1.41. The business has a 50 day moving average of $4.00 and a two-hundred day moving average of $4.37.
Endo International (NASDAQ:ENDP) (TSE:ENL) last announced its quarterly earnings results on Monday, November 4th. The company reported $0.60 earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of $0.53 by $0.07. Endo International had a negative return on equity of 105.36% and a negative net margin of 16.89%. The company had revenue of $729.00 million during the quarter, compared to the consensus estimate of $709.01 million. During the same period in the previous year, the company posted $0.71 earnings per share. Endo International’s revenue for the quarter was down 2.1% on a year-over-year basis. On average, equities research analysts anticipate that Endo International will post 2.18 EPS for the current year.
In other news, Director Roger H. Kimmel sold 25,000 shares of the business’s stock in a transaction that occurred on Monday, September 16th. The stock was sold at an average price of $4.09, for a total value of $102,250.00. Following the completion of the sale, the director now directly owns 123,309 shares in the company, valued at $504,333.81. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. 1.50% of the stock is owned by insiders.
Several institutional investors have recently bought and sold shares of ENDP. Arizona State Retirement System increased its position in shares of Endo International by 1.4% in the second quarter. Arizona State Retirement System now owns 312,262 shares of the company’s stock valued at $1,287,000 after buying an additional 4,167 shares in the last quarter. Systematic Financial Management LP increased its position in shares of Endo International by 63.4% during the second quarter. Systematic Financial Management LP now owns 193,380 shares of the company’s stock worth $797,000 after purchasing an additional 75,035 shares in the last quarter. Meeder Asset Management Inc. increased its position in shares of Endo International by 47.1% during the second quarter. Meeder Asset Management Inc. now owns 37,887 shares of the company’s stock worth $156,000 after purchasing an additional 12,127 shares in the last quarter. Connor Clark & Lunn Investment Management Ltd. increased its position in shares of Endo International by 61.2% during the second quarter. Connor Clark & Lunn Investment Management Ltd. now owns 3,063,703 shares of the company’s stock worth $12,622,000 after purchasing an additional 1,163,289 shares in the last quarter. Finally, Hunter Associates Investment Management LLC increased its position in shares of Endo International by 37.4% during the second quarter. Hunter Associates Investment Management LLC now owns 94,075 shares of the company’s stock worth $388,000 after purchasing an additional 25,625 shares in the last quarter. Institutional investors and hedge funds own 95.20% of the company’s stock.
About Endo International
Endo International plc, a specialty pharmaceutical company, manufactures and sells generic and branded pharmaceuticals in the United States, Canada, and internationally. The company operates through three segments: U.S. Generic Pharmaceuticals, U.S. Branded Pharmaceuticals, and International Pharmaceuticals.
Featured Article: Monthly Dividend Stocks
To view ValuEngine’s full report, visit ValuEngine’s official website.
Receive News & Ratings for Endo International Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Endo International and related companies with MarketBeat.com's FREE daily email newsletter.